Cargando…
Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies
IMPORTANCE: High costs and risks of research and development (R&D) have been used to justify the high prices of cancer drugs. However, what the return on R&D investment is, and by extension what a justifiable price might be, is unclear. OBJECTIVE: To compare incomes from the sales of cancer...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Medical Association
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324319/ https://www.ncbi.nlm.nih.gov/pubmed/30644967 http://dx.doi.org/10.1001/jamanetworkopen.2018.6875 |